Human ERBB2 Stable Cell Line - SK-BR-3

The ERBB2 gene, also known as HER2 (human epidermal growth factor receptor 2), encodes a transmembrane tyrosine kinase belonging to the EGFR family. ERBB2 lacks a known high-affinity ligand; it remains in its active conformation and serves as the preferred dimeric partner for other EGFR family members, such as HER1 and HER3. ERBB2 heterodimerization triggers potent downstream signaling via the PI3K/Akt and MAPK/ERK pathways, which are key drivers of cell proliferation and survival. Clinically, ERBB2 amplification or overexpression is observed in approximately 15-30% of breast cancers and is associated with aggressive disease. The discovery of HER2 has spurred the development of several transformative therapies, including monoclonal antibodies (e.g., trastuzumab), tyrosine kinase inhibitors (e.g., lapatinib), and antibody-drug conjugates (e.g., T-DM1). Besides breast cancer, ERBB2 amplification is also an important therapeutic target for gastric and lung cancer.

The stable human ERBB2 cell line constructed in the SK-BR-3 context is the gold standard model for studying HER2-positive breast cancer and developing targeted anticancer therapies. SK-BR-3 is a human breast adenocarcinoma cell line derived from pleural effusion, characterized by naturally high levels of HER2 amplification and the absence of estrogen and progesterone receptors. This cell line provides a stable and high-density target for HER2 signaling pathway research, enabling precise measurement of receptor phosphorylation kinetics and downstream pathway activation. This product is widely used in the pharmaceutical industry for high-throughput screening of novel HER2 inhibitors and efficacy testing of next-generation antibody-drug conjugates (ADCs) and combination therapies. The ERBB2-SK-BR-3 model is also an important tool for studying the molecular mechanisms of resistance to current HER2-targeted drugs, such as kinase domain mutations or bypass signaling pathway activation.